Test, track, treat using wearable sensors for management of Parkinson’s disease: 12‑month prospective observational United Arab Emirates study using Parkinson’s Kinetograph (EmPark-PKG Study) DOI Creative Commons
Vinod Metta, Mubasher A. Qamar, Karolina Popławska-Domaszewicz

et al.

Journal of Neural Transmission, Journal Year: 2024, Volume and Issue: unknown

Published: Dec. 27, 2024

Parkinson's disease (PD) is a progressive neurodegenerative disorder marked by both motor and non-motor symptoms that necessitate ongoing clinical evaluation medication adjustments. Home-based wearable sensor monitoring offers detailed continuous record of patient symptoms, potentially enhancing management. The EmPark-PKG study aims to evaluate the effectiveness KinetoGraph (PKG), device, in tracking progression over 12 months Emirati non-Emirati PD patients. Fifty patients (32% Emirati, 68% non-Emirati) were assessed at baseline 12-month follow-up. Clinical evaluations included levodopa equivalent daily dosage (LEDD) assessments. Concurrently, PKG provided metrics such as bradykinesia score (BKS) dyskinesia (DKS). Statistical analyses conducted determine changes from six months, differences between groups, correlations Significant reductions LEDD improvements scores observed (p < 0.05). PKG-guided adjustments associated with enhanced outcomes Specifically, exhibited significant reduction (Z = − 2.010, p 0.044), whereas did not 0.468, 0.640). Both groups showed scale complication scores. Spearman correlation analysis revealed strong relationships subjective assessments 0.001). demonstrates potential benefits remote for personalised symptom management PD. supports stepped care paradigm enabling bespoke titration based on objective data, facilitating tailored effective care.

Language: Английский

Parkinson’s Disease Detection Using Advanced Wave Signal Processing on Spiral Drawing Tests DOI
S.P. Sasirekha, Ravi Shankar,

S. Duraisamy

et al.

Communications in computer and information science, Journal Year: 2025, Volume and Issue: unknown, P. 35 - 53

Published: Jan. 1, 2025

Language: Английский

Citations

0
Addressing the Ethnicity Gap in Catechol O-Methyl Transferase Inhibitor Trials in Parkinson’s Disease: A Review of Available Global Data DOI Open Access
Karolina Popławska-Domaszewicz,

Naomi Limbachiya,

Mubasher A. Qamar

et al.

Journal of Personalized Medicine, Journal Year: 2024, Volume and Issue: 14(9), P. 939 - 939

Published: Sept. 3, 2024

Catechol-O-methyltransferase inhibitors (COMT-Is) have significantly improved the quality of life and symptom management for those at advanced stages Parkinson’s Disease (PD). Given that PD is one fastest-growing neurodegenerative diseases worldwide, there a need to establish clear framework systematic distribution COMT-Is, considering inter-individual intra-individual variations in patient response. One major barrier this underrepresentation ethnic minority participants clinical trials investigating COMT-Is. To investigate this, we performed narrative review. We searched PubMed COMT-Is patients with examined diversity cohorts. A total 63 articles were identified, 34 found match our inclusion criteria. Among meeting criteria, only 8 reported participants’ backgrounds. Our findings reveal consistent groups cohorts—a trend reflects broader concerns across research. In review, explore potential reasons minorities propose strategies address issue.

Language: Английский

Citations

2
Test, track, treat using wearable sensors for management of Parkinson’s disease: 12‑month prospective observational United Arab Emirates study using Parkinson’s Kinetograph (EmPark-PKG Study) DOI Creative Commons
Vinod Metta, Mubasher A. Qamar, Karolina Popławska-Domaszewicz

et al.

Journal of Neural Transmission, Journal Year: 2024, Volume and Issue: unknown

Published: Dec. 27, 2024

Parkinson's disease (PD) is a progressive neurodegenerative disorder marked by both motor and non-motor symptoms that necessitate ongoing clinical evaluation medication adjustments. Home-based wearable sensor monitoring offers detailed continuous record of patient symptoms, potentially enhancing management. The EmPark-PKG study aims to evaluate the effectiveness KinetoGraph (PKG), device, in tracking progression over 12 months Emirati non-Emirati PD patients. Fifty patients (32% Emirati, 68% non-Emirati) were assessed at baseline 12-month follow-up. Clinical evaluations included levodopa equivalent daily dosage (LEDD) assessments. Concurrently, PKG provided metrics such as bradykinesia score (BKS) dyskinesia (DKS). Statistical analyses conducted determine changes from six months, differences between groups, correlations Significant reductions LEDD improvements scores observed (p < 0.05). PKG-guided adjustments associated with enhanced outcomes Specifically, exhibited significant reduction (Z = − 2.010, p 0.044), whereas did not 0.468, 0.640). Both groups showed scale complication scores. Spearman correlation analysis revealed strong relationships subjective assessments 0.001). demonstrates potential benefits remote for personalised symptom management PD. supports stepped care paradigm enabling bespoke titration based on objective data, facilitating tailored effective care.

Language: Английский

Citations

0